Nixon 250 mg IM/IV Injection: Each vial contains dry powder equivalent to 250 mg Ceftriaxone (as sterile Ceftriaxone Sodium USP) and each ampoule contains 2 ml Lidocaine HCI USP1% injection for IM injection or 5 ml Water for injection USP for IV injection.
Nixon 500 mg IM/IV Injection: Each vial contains dry powder equivalent to 500 mg Ceftriaxone (as sterile Ceftriaxone Sodium USP) and each ampoule contains 2 ml Lidocaine HCI USP1% injection for IM injection or 5 ml Water for injection USP for IV injection.
Nixon 1 g IM/IV Injection: Each vial contains dry powder equivalent to 1 g Ceftriaxone (as sterile Ceftriaxone Sodium USP) and each ampoule contains 3.5 ml Lidocaine HCI USP 1% injection for IM injection or 10 ml Water for injection USP for IV injection.
Nixon 2 g IV Injection: Each vial contains dry powder equivalent to 2 g Ceftriaxone (as sterile Ceftriaxone Sodium USP) and each of two ampoules contains 10 ml Water for injection USP for IV injection.
Nixon is indicated for the treatment of the following major infections:
* Renal and urinary tract infections
* Lower respiratory tract infections, particularly pneumonia
* Gonococcal infections
* Skin, soft tissue, bone and joint infections
* Bacterial meningitis
* Serious bacterial infections e.g. septicemia
* ENT infections
* Infections in cancer patients
* Prevention of postoperative infections
* Perioperative prophylaxis of infections associated with surgery
* Typhoid fever
